Karyopharm Therapeutics Inc Stock Price, News & Analysis

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) reported financial results for Q2 2024, achieving total revenue of $42.8 million and U.S. XPOVIO® net product revenue of $28.0 million. The company highlighted:

1. Updated clinical results from the SIENDO study showing promising PFS in endometrial cancer subgroups.

2. Completion of refinancing transactions extending debt maturities to 2028 and 2029.

3. Raised lower end of 2024 revenue guidance to $145.0-$160.0 million.

4. Lowered 2024 R&D and SG&A expense guidance to $250.0-$265.0 million.

5. Reported net income of $23.8 million for Q2 2024.

6. Cash position of $152.5 million as of June 30, 2024.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced the granting of 14,000 restricted stock units (RSUs) to four newly-hired employees. These RSU awards, granted on July 31, 2024, are part of the Company's 2022 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, with 33 1/3% vesting on each anniversary of the grant date, subject to continued employment. In the event of a 'change in control,' the RSUs may become fully exercisable if the employee's employment is terminated under specific conditions within one year of the event.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024. The company's management team will host a conference call and audio webcast at 8:00 a.m. ET on the same day to discuss the financial results and provide company updates.

Investors and interested parties can access the conference call by dialing (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes before the start time. A live audio webcast of the call, along with accompanying slides, will be available on the company's website under the 'Events & Presentations' section. An archived version of the webcast will be accessible approximately two hours after the event.

Karyopharm Therapeutics (Nasdaq: KPTI) has granted 8,800 restricted stock units (RSUs) to three newly-hired employees as of June 30, 2024, under its 2022 Inducement Stock Incentive Plan.

The RSUs are an inducement for employment and will vest over three years, with one-third vesting on each anniversary of the grant date. These awards are subject to the employees' continued service. Additionally, full vesting will occur if employment is terminated for 'good reason' or without 'cause' within one year following a change in control event.

Karyopharm Therapeutics, a commercial-stage pharmaceutical company, announced the grant of 9,500 restricted stock units (RSUs) to three newly-hired employees and 200,000 RSUs to Dr. Michael Method, Senior VP of Clinical Development. These grants, effective May 31, 2024, were made under the 2022 Inducement Stock Incentive Plan and follow Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on continued employment. Immediate full vesting occurs if employment is terminated for 'good reason' or without 'cause' within one year of a 'change in control event.' Keywords: KPTI, Karyopharm, RSUs, Nasdaq, restricted stock units.

Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months for selinexor-treated patients versus 5.2 months for the placebo group. Additionally, a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis showed a mean of 26 months for selinexor compared to 15 months for placebo. No new safety signals were identified. The exploratory subgroup analysis highlighted promising efficacy signals, with ongoing Phase 3 trials expected to provide definitive results by mid-2025.

Karyopharm Therapeutics (Nasdaq: KPTI) announced that its senior management will participate in the Jefferies Global Healthcare Conference on June 5, 2024, in New York. The event includes a fireside chat at 1:00 p.m. ET. A live webcast and slides will be available on the company's website under the 'Events & Presentations' section and for replay afterward.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will participate in the 2024 RBC Capital Markets Global Healthcare Conference with a fireside chat on May 15. The live webcast can be accessed on the company's website.

Karyopharm Therapeutics Inc. announced significant refinancing transactions, extending the vast majority of its debt maturities to 2028 and 2029. The company exchanged $148.0 million of existing convertible notes due in 2025 for $111.0 million of new convertible notes due in 2029 and warrants. Additionally, a new $100.0 million senior secured term loan was issued, repaying principal portions and amending a royalty agreement with HealthCare Royalty. These transactions fortify the company's balance sheet and enhance its ability to unlock the potential of selinexor.